Lyrica (Pregabalin) Dosing Guidelines
Start Lyrica at 150 mg/day (50 mg three times daily or 75 mg twice daily) for most neuropathic pain conditions, titrate to 300 mg/day within one week based on tolerability, and adjust doses downward by 50% for each 50% reduction in creatinine clearance below 60 mL/min. 1
Indication-Specific Dosing
Diabetic Peripheral Neuropathy
- Starting dose: 50 mg three times daily (150 mg/day)
- Target dose: 100 mg three times daily (300 mg/day) within 1 week
- Maximum dose: 300 mg/day
- Key point: Doses above 300 mg/day are NOT recommended—600 mg/day showed no additional benefit and worse tolerability 1
Postherpetic Neuralgia
- Starting dose: 75 mg twice daily OR 50 mg three times daily (150 mg/day)
- Target dose: 300 mg/day within 1 week
- Maximum dose: 600 mg/day (300 mg twice daily OR 200 mg three times daily)
- Titration strategy: Reserve doses above 300 mg/day only for patients with ongoing pain who tolerate 300 mg/day after 2-4 weeks 1
Partial Onset Seizures (Adjunctive)
- Starting dose: ≤150 mg/day (75 mg twice daily OR 50 mg three times daily)
- Maximum dose: 600 mg/day
- Dosing frequency: Two or three divided doses daily 1
Fibromyalgia
- Starting dose: 75 mg twice daily (150 mg/day)
- Target dose: 300-450 mg/day
- Titration: Increase to 150 mg twice daily (300 mg/day) within 1 week; if insufficient benefit, increase to 225 mg twice daily (450 mg/day)
- Maximum dose: 450 mg/day (600 mg/day showed no additional benefit) 1
Spinal Cord Injury Neuropathic Pain
- Starting dose: 75 mg twice daily (150 mg/day)
- Target dose: 150 mg twice daily (300 mg/day) within 1 week
- Maximum dose: 300 mg twice daily (600 mg/day) after 2-3 weeks if inadequate relief 1
Renal Impairment Dosing (Critical)
Pregabalin is eliminated 98% unchanged by the kidneys—dose adjustment is mandatory for CLcr <60 mL/min 1, 2. Calculate creatinine clearance using Cockcroft-Gault equation, then adjust as follows:
| CLcr (mL/min) | Daily Dose Range | Frequency |
|---|---|---|
| ≥60 | 150-600 mg | BID or TID |
| 30-60 | 75-300 mg | BID or TID |
| 15-30 | 25-150 mg | QD or BID |
| <15 | 25-75 mg | QD |
Hemodialysis Patients
- Adjust daily dose based on renal function (see table above)
- Add supplemental dose immediately after each 4-hour hemodialysis session:
- 25 mg QD regimen: add 25-50 mg post-dialysis
- 25-50 mg QD regimen: add 50-75 mg post-dialysis
- 50-75 mg QD regimen: add 75-100 mg post-dialysis
- 75 mg QD regimen: add 100-150 mg post-dialysis 1
Clinical pearl: Pregabalin clearance is directly proportional to creatinine clearance (56% correlation), making renal dosing adjustments highly predictable 2.
Administration Details
- Food: Can be taken with or without food—no clinically relevant effect on absorption 1, 3
- Onset: Steady state achieved within 24-48 hours; efficacy may be observed as early as day 2 3
- Discontinuation: Taper gradually over minimum 1 week to avoid withdrawal 1
- Oral solution: 20 mg/mL concentration; prescribe in mg, pharmacist converts to mL 1
Titration Strategy from Guidelines
The Mayo Clinic neuropathic pain guidelines 4 recommend:
- Starting: 50 mg three times daily OR 75 mg twice daily
- Increase to 300 mg/day after 3-7 days
- Further increase by 150 mg/day every 3-7 days as tolerated
- Maximum: 600 mg/day (200 mg three times daily OR 300 mg twice daily)
- Trial duration: 4 weeks at target dose to assess efficacy
This aligns with FDA labeling but emphasizes the 3-7 day titration intervals for tolerability 4.
Critical Warnings
CNS Depression Risk
Exercise extreme caution when combining pregabalin with other CNS depressants (especially baclofen) in patients with ANY degree of renal impairment—even mild renal dysfunction (eGFR 77 mL/min) has resulted in severe somnolence and coma requiring drug discontinuation 5. Start with reduced doses in at-risk patients.
Dose-Dependent Adverse Effects
The most common side effects are dizziness (23.1%), somnolence (14.6%), and peripheral edema (10.4%)—all dose-dependent 6. These typically resolve with dose reduction without requiring discontinuation.
Pharmacokinetic Advantages
Pregabalin has linear, predictable pharmacokinetics with no hepatic metabolism, no protein binding, and no cytochrome P450 interactions—making drug-drug interactions unlikely 3, 7. This allows for straightforward dosing without concern for most medication interactions.